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Abstract
This editorial article summarizes the achievements and
current challenges for the Journal of Circulating Biomarkers
(JCB) regarding a more strategic approach to branding and
attracting a high quality variety of articles. More emphasis
is placed on fostering engagement with academic and
industry sources operating at the cutting-edge of transla‐
tional technologies applied to the field of circulating
biomarkers (interface between extracellular vesicles
including exosomes and microvesicles, circulating tumour
cells, cell-free circulating DNA and circulating protein
markers) and with those in the investment arena seeking
and providing private funding for this area of research.
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We are proud to announce that during the past year we
have experienced several ongoing developments, one of
which has been the expansion of our editorial board with
key opinion leaders in the circulating biomarker field
including Yvon E. Cayre (Pierre and Marie Curie Univer‐
sity, France), Alain Charest (Tufts University School of
Medicine, USA), Yong Chen (Ecole Normale Superieure,
France), Daniel Haber (Harvard Medical School, USA),
Pavel Laktionov (Russian Academy of Sciences, Russian
Federation) and David T. Wong (University of California
Los Angeles, USA), all of whom contribute as part of our
associate editor’s team. Additionally, Aled Clayton
(Cardiff University, United Kingdom), Aleksandra Fučić
(Institute for Medical Research and Occupational Health,
Croatia), Stefan Holdenrieder (University Hospital Bonn,
Germany), Hongjun Kang (Chinese PLA General Hospital,
China), Ming-Lin Liu (University of Pennsylvania, USA),
Jan Lotvall (Göteborgs Universitet, Sweden), Jie Ma (Fudan
University, China), Pierre-Yves Mantel (Harvard School of
Public Health, USA), Dario Marchetti (Baylor College of
Medicine, USA), P. Shannon Pendergras (Ymir Genomics,
USA), Eva Rohde (Paracelsus Medical University, Austria),
An Song (Genentech Inc., USA), Matthew J. Wood (Uni‐
versity of Oxford, United Kingdom), Bruce R. Zetter
(Harvard Medical School, USA) and Hanyu Zhu (Chinese
PLA General Hospital, China) serve as members of our
editorial board.
In 2014, we published high quality papers covering
research topics in the area of cell-cell communication via
exosomal heat-shock proteins, the function of erythrocyte-
derived extracellular vesicles in malaria as it pertains to
understanding their role in immune regulation and cell-cell
communication, the development of stem cell-derived
exosomes as a cell-free regenerative medicine, as well as the
detection of human c-Myc and EGFR amplifications in
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circulating extracellular vesicles in mouse tumour models.
We also published a paper on circulating free DNA and the
influence thereof following lung parenchyma surgical
manipulation.
In addition, we are pleased to have established a partner‐
ship/collaboration with the BioPharma Research Council
(http://www.biopharmaresearchcouncil.org/), spearhead‐
ed by its Executive Director, Joanne Gere. The BioPharma
Research Council has been developing a vibrant commun‐
ity for scientists as they navigate today's complex science
environments. Our unique resources – including close
relationships with leading companies and suppliers – and
agile approaches have established recurrent opportunities
for breakthrough discussion and debate throughout the
drug discovery process and delivery pipeline. This part‐
nership/collaboration resulted in the establishment of a
short course titled, “Extracellular Vesicles: The Transition
from Tissue to Liquid Biopsies”, which was conducted as
a four-session webinar series in October and November
2014. The goal of the course was to provide, at an introduc‐
tory level, an exchange between researchers from within
academia and industry pertaining to the characterization
of the applications of EVs in clinical and translational
research, eventually to be implemented within clinical
practice. We were able to utilize our editorial team to
present topics that included: “Overview of Extracellular
Vesicles” by Jan Lötvall, MD, PhD; “Clinical Diagnostic
Applications of Extracellular Vesicles” by Johan Skog, PhD;
“Commercialization Aspects of Extracellular Vesicles” by
Alexander “Sasha” Vlassov, PhD; “Extracellular Vesicles:
Therapeutic Hurdles” by Eva Rohde, MD; “Funding
Opportunities for Extracellular Vesicle Research” by Angel
Ayuso Sacido, PhD. A meeting dispatch was published




experience, we learned that coordinating the preparation
process of such webinars required approximately six
months. We plan to continue several webinar series on
circulating tumour cells and cell-free circulating DNA later
this year.
Finally, we launched a special issue titled, “The Biology and
the Clinical Utility of Circulating Tumor Cells”, with a
focus on detecting the latest findings in CTC research and
clinical value. More details are located in the news section
of the Journal of Circulating Biomarkers (http://www.inte‐
chopen.com/journals/journal-of-circulating-biomarkers).
As we continue to strive to publish the best scientific
research in all fields related to circulating biomarkers, the
editorial team aims to focus on additional topics such as cell
free DNA and disruptive technologies, among others.
JCB accepts original and review articles, as well as editori‐
als, perspectives, short research reports, protocols and
methods, notes to the editor, letters to the editor and
meeting dispatch reports. We would also like to mention
that InTech Publishing have decided that JCB will not apply
any article processing charges for authors whose research
papers have been accepted for publication in Volume
4/2015 of the journal. All manuscripts are peer-reviewed for
scientific quality and the review process is conducted
entirely online. The editorial manager facilitates the
manuscript processing time, thereby reducing costs and
providing a better experience to both our authors and
reviewers. We have received numerous positive comments
about this evolving electronic system and are indebted to
InTech for managing this programme for us. For more
information, please review our new manuscript submis‐
sion system at http://www.editorialmanager.com/exo/
default.asp. In addition, we are expediting the acceptance
to publishing time for our authors and will request informal
opinions from our editorial board for borderline cases.
JCB will continue to partner with scientific societies and
academic and industry leaders in order to advance the field
and to allow free access to knowledge in the area of
circulating biomarkers.
We gratefully acknowledge the editorial team and publish‐
ers for making the continued success of the journal possible.
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